In this report, we review the clinical, biochemical, pathophysiologic, and therapeutic aspects of cerebrotendinous xanthomatosis. We stress the importance of early diagnosis and treatment. In addition, we describe our experience in treating patients with chenodeoxycholic acid, an essential drug for this disorder that is no longer available. ( J Child Neurol 2003;18:633—638).
Get full access to this article
View all access options for this article.
References
1.
van Bogaert L. , Scherer HJ, Epstein E.: Une Forme Cerebrale de la Cholesterinose Generalisee, Paris, Masson et Cie , 1937.
2.
Cruysberg JR , Wevers RA, Tolboom JJ: Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol1991;112:606—607.
3.
van Heijst AF , Verrips A., Wevers RA, et al: Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr1998;157:313—316.
4.
Bindl L., Lutjohann D., Lentze MJ, von Bergmann K.: Cerebrotendinous xanthomatosis presenting as “chologenic diarrhoea.”Acta Paediatr2001;90:828—829.
5.
Verrips A., van Engelen BG, Wevers RA, et al: Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol2000;57:520—524.
6.
Clayton PT, Verrips A., Sistermans E., et al: Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis2002;25:501—513.
7.
Dotti MT, Salen G., Federico A.: Cerebrotendinous xanthomatosis as a multisystem disease mimicking premature ageing. Dev Neurosci1991;13:371—376.
8.
Dotti MT, Rufa A., Federico A.: Cerebrotendinous xanthomatosis: Heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings. J Inherit Metab Dis2001;24:696—706.
9.
Gilad R., Lampl Y., Lev D., Sadeh M.: Cerebrotendinous xanthomatosis without xanthomas. Clin Genet1999;56:405—406.
10.
Salen G., Shefer S., Berginer VM: Familial diseases with storage of sterols other than cholesterol: Cerebrotendinous xanthomatosis and sitosterolemia with xantomatosis, in Stanbury JB, Wyngarden JB, Frederickson DS, et al (eds): The Metabolic Basis of Inherited Disease, 5th ed. New York, McGraw-Hill, 1983,713-730.
11.
Fujiyama J., Kuriyama M., Arima S., et al: Atherogenic risk factors in cerebrotendinous xanthomatosis. Clin Chim Acta1991;200:1—11.
12.
Kerleau JM, Lefebvre H., Houdent C., Wolf LM: L'atherome coronien precoce. Une complicance peu connue de la xanthomatose cerebrotendineuse, letter. Presse Med1993 ;22:1460.
13.
Dotti MT, Mondillo S., Plewnia K., et al: Cerebrotendinous xanthomatosis: Evidence of lipomatous hypertrophy of the atrial septum. J Neurol1998;245:723—726.
14.
Kawabata M., Kuriyama M., Mori S., et al: Pulmonary manifestations in cerebrotendinous xanthomatosis. Intern Med1998;37:922—926.
15.
Berginer VM, Shany S., Alkalay D., et al: Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism1993;42:69—74.
16.
Federico A. , Dotti MT, Lorè F., Nuti R.: Cerebrotendinous xanthomatosis: Pathophysiological study on bone metabolism. J Neurol Sci1993 ;115:67—70.
17.
Sugama S., Kimura A., Chen W., et al: Frontal lobe dementia with abnormal cholesterol metabolism and heterozygous mutation in sterol 27-hydroxylase gene (CYP27). J Inherit Metab Dis2001;24:379—392.
18.
van Bogaert L.: Le cadre des xanthomatoses et leurs different types: Xanthomatoses secondaire. Rev Med1961 ;17:433—443.
19.
Verrips A., Nijeholt GJ, Barkhof F., et al: Spinal xanthomatosis: A variant of cerebrotendinous xanthomatosis . Brain1999;122: 1589—1595.
20.
Fiorelli M. , Di Piero V, Bastianello S., et al: Cerebrotendinous xanthomatosis: Clinical and MRI study (a case report). J Neurol Neurosurg Psychiatry1990;53:76—78.
21.
Rogelet P., Gerard JM, Michotte A., et al: Xanthomatose cerebrotendineuse. Deux cas avec imagerie par resonance magnetique. Rev Neurol1992;148:541—545.
22.
Ohno T., Kobayashi S., Hayashi M., et al: Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: Long-term follow up of three patients. J Neurol Sci2001;182:95—97.
23.
Grandas F., Martin-Moro M., Garcia-Munozguren S., Anaya F.: Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord2002;17:1396—1397.
24.
Matsumuro K. , Takahashi K., Matsumoto H., et al: A case of cerebrotendinous xanthomatosis with convulsive seizures. Rinsho Shinkeigaku1990;30:207—209.
25.
Arlazoroff A., Roitberg B., Werber E., et al: Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia1991;32:657—661.
26.
Berginer VM , Radwan H., Korczyn AD, et al: EEG in cerebrotendinous xanthomatosis (CTX). Clin Electroencephalogr1982;13:89—96.
27.
Tokimura Y. , Kuriyama M., Arimura K., et al: Electrophysiological studies in cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry1992;55:52—55.
28.
Mondelli M. , Rossi A., Scarpini C., et al: Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol1992;49:469—475.
29.
Pop PH, Joosten E., van Spreeken A., et al: Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX). Acta Neuropathol (Berl)1984;64:259—264.
30.
Berginer VM , Berginer J., Salen G., et al: Computed tomography in cerebrotendinous xanthomatosis. Neurology1981;31:1463—1465.
31.
Waterreus RJ , Koopman BJ, Wolthers BG, Oosterhuis HJ: Cerebrotendinous xanthomatosis (CTX): A clinical survey of the patient population in The Netherlands. Clin Neurol Neurosurg1987;89:169—175.
32.
Berginer VM , Berginer J., Korczyn AD, Tadmor R.: Magnetic resonance imaging in cerebrotendinous xanthomatosis: A prospective clinical and neuroradiological study. J Neurol Sci1994;122:102—108.
33.
Dotti MT, Federico A., Signorini E., et al: Cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease): CT and MR findings. AJNR Am J Neuroradiol1994;15:1721—1726.
34.
Barkhof F., Verrips A., Wesseling P., et al: Cerebrotendinous xanthomatosis: The spectrum of imaging findings and the correlation with neuropathologic findings. Radiology2000;217:869—876.
35.
De Stefano N, Dotti MT, Mortilla M., Federico A.: Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain2001;124:121—131.
36.
Inglese M., De Stefano N, Pagani E., et al: Quantification of brain damage in cerebrotendinous xanthomatosis with magnetization transfer MR imaging. AJNR Am J Neuroradiol2003;24:495—500.
37.
Verrips A., Wevers RA, van Engelen BG, et al: Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism1999;48:233—238.
38.
Argov Z., Soffer D., Eisenberg S., Zimmerman Y.: Chronic demyelinating peripheral neuropathy in cerebrotendinous xanthomatosis . Ann Neurol1986;20:89—91.
39.
Ben Hamida M , Chabbi N., Ben Hamida C, et al: Neuropatie peripherique dans un cas sporadique de xanthomatose cerebrotendineuse. Rev Neurol1991;147:385—388.
40.
Federico A. , Dotti MT, Volpi N.: Muscle mitochondrial changes in cerebrotendinous xanthomatosis. Ann Neurol1991;30:734—735.
41.
Verrips A., van Engelen BG, ter Laak H., et al: Cerebrotendinous xanthomatosis. Controversies about nerve and muscle: Observations in ten patients. Neuromuscul Disord2000;10:407—414.
Menkes JH, Schimschock JR, Swanson PD: Cerebrotendinous xanthomatosis: The storage of cholestanol within the nervous system. Arch Neurol1968;19:47—53.
44.
Cali JJ, Russell DW: Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis . J Biol Chem1991;266:7774—7778.
45.
Cali JJ, Hsieh CL, Francke U., Russell DW: Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem1991;266:7779—7783.
46.
Verrips A., Hoefsloot LH, Steenbergen GC, et al: Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain2000 ;123:908—919.
47.
Inoue K., Kubota S., Seyama Y.: Cholestanol induces apoptosis of cerebellar neuronal cells. Biochem Biophys Res Commun1999;256:198—203.
48.
Berginer VM , Salen G., Shefer S.: Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med1984 ;311:1649—1652.
49.
Mondelli M. , Sicurelli F., Scarpini C., et al: Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci2001;190:29—33.
50.
Samenuk P., Koffman BM: Chenodeoxycholic treatment of cerebrotendinous xanthomatosis. Neurology2001;56:695—696.
51.
Salen G.: Chenodeoxycholic treatment of cerebrotendinous xanthomatosis, letter. Neurology2001;56:696.
52.
Federico A. , Dotti MT: Cerebrotendinous xanthomatosis. Neurology2001;57:1743.
53.
Peynet J., Laurent A., De Liege P, et al: Cerebrotendinous xanthomatosis: Treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. Neurology1991;41:434—436.
54.
Federico A. , Dotti MT: Treatment of cerebrotendinous xanthomatosis . Neurology1994;44:2218.
55.
Berginer VM , Salen G.: LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. J Neurol Sci1994;121:229—232.
56.
Mimura Y., Kuriyama M., Tokimura Y., et al: Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci1993;114:227—230.
